Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) have become the first targeted therapies available in the treatment of patients with high-grade serous ovarian cancer (HGSOC). We recently described a significant reduction in PARP1 protein levels in vitro and in vivo in patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Baloch, Tahira, López-Ozuna, Vanessa M., Wang, Qiong, Matanis, Emad, Kessous, Roy, Kogan, Liron, Yasmeen, Amber, Gotlieb, Walter H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327434/
https://www.ncbi.nlm.nih.gov/pubmed/30630446
http://dx.doi.org/10.1186/s12885-018-5250-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327434/
https://www.ncbi.nlm.nih.gov/pubmed/30630446
http://dx.doi.org/10.1186/s12885-018-5250-4

Ejemplares similares